It's very interesting to hear that. Hopefully through this committee, perhaps some provincial agencies will be compelled to respond to that.
I also wanted to talk about your indication that the generic drug market appears to face more shortages than the brand name market. Can you identify why you think that is? Also, what policy ramifications do you think that has as we consider the balance between generics and brand name pharmaceuticals? What does that tell us going forward, if there are more shortages on the generic side than the brand name side?